Johnson & Johnson
Change company Symbol lookup
Select an option...
JNJ Johnson & Johnson
TATT TAT Technologies Ltd
STOR STORE Capital Corp
NGG National Grid PLC
MDXG MiMedx Group Inc
GOGR Go Green Global Technologies Corp
APINX AMG Beutel Goodman International Equity Fund - Class N
SVBL Silver Bull Resources Inc
MYMD MyMD Pharmaceuticals Inc

Health Care : Pharmaceuticals | Large Cap Blend
Company profile

Johnson & Johnson is a diversified healthcare products company. The Company is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer Health, Pharmaceutical and MedTech. Its primary focus is products related to human health and well-being. The Consumer Health segment includes a range of products that is focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension. The MedTech segment includes a range of products used in the interventional solutions, orthopaedics, surgery, and vision fields. Its geographic area includes the United States, Europe, Western Hemisphere (excluding the United States), and Africa, Asia and Pacific.


Last Trade
0.08 (0.05%)
B/A Size

Market Hours

Closing Price
Day's Change
-6.23 (-3.70%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Piedmont Lithium receives $141.7 million DOE grant, as stock has rocketed over 60% in 3 months

12:25 pm ET October 19, 2022 (MarketWatch)

This replaces an earlier item that reported incorrect year-to-date share gains for Piedmont Lithium and Livent. It has been corrected.

Shares of Piedmont Lithium Inc. charged up 11.5% in midday trading Wednesday, after the lithium producer announced a $141.7 million grant from the U.S. Department of Energy. The company said the grant is part of the Biden administration's infrastructure law aimed at expanding domestic manufacturing of batteries for electric vehicles (EVs) and for materials currently imported. Piedmont, which has yet to report any revenue, said the grant will support the construction of its $600 million Tennessee Lithium project, which is expected to begin in 2023, and to produce 30,000 metric tons of lithium hydroxide per year. The project is expected to create about 120 new jobs. "This funding will enable us to accelerate detailed engineering and place orders for long-lead items," said Piedmont Chief Operating Officer Patrick Brindle. The stock has rallied 63.8% over the past three months, while fellow lithium producer Livent Corp.'s shares have blasted run up% higher and the S&P 500 has lost 6.1%.

-Tomi Kilgore


(END) Dow Jones Newswires

October 19, 2022 12:25 ET (16:25 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.